ImmunityBio Inc IBRX

Vanguard’s six reporting entities collectively held 36.48 million shares after adding a net 2.43 million during Q2.

ImmunityBio stock climbed over the $10 mark for the first time since March this year.

The GA-Courtenay Special Situations Fund is an investment fund managed by Green Ash Partners. The fund focuses on special situations and high-growth equities. You can download the July letter here. The fund reported a 13.8% decline in July, bringing its year-to-date performance to -10.0%. The fund attributed the decline to an unusual liquidity-driven dislocation across […]

IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.

ImmunityBio Inc. (NASDAQ:IBRX) saw its share price jump by 9.94 percent on Tuesday to finish at $9.29 apiece following a high-profile meeting between its founder, Dr. Patrick Soon-Shiong, and Turkish President Recep Tayyip Erdogan, fueling optimism around the listed firm’s planned expansion into Turkey. The Turkish government posted a photo of Erdogan and Soon-Shiong on […]

Soon-Shiong owned 65.5% of ImmunityBio as of its April proxy record date.

Nant Capital’s investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong’s new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio’s share price has cooled slightly in the very short term, with a 1-day share price return of 2.75% and a 7-day share price return of 1.81%. However, the 30-day and 90-day share price returns of 7.53% and 16.45% suggest momentum is still building...

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.

Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction. The round was led by

ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.

A new patent application covers using Anktiva to restore immune cells depleted by cancer treatments.

Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.

Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.

Patrick Soon-Shiong said the trial has been fully accrued and passed its one-year mark.

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.